242 related articles for article (PubMed ID: 33247691)
1. Efficacy of Oral Vitamin A in Reducing β-hCG Levels in Low-Risk Gestational Trophoblastic Neoplasia Patients.
Hidayat YM; Darmadi A E; Rachmayati S; Kusumah WP; Djuwantono T; Pramatirta AY; Suardi D
Asian Pac J Cancer Prev; 2020 Nov; 21(11):3325-3329. PubMed ID: 33247691
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Combination Therapy with Actinomycin D and Methotrexate in the Treatment of Low-Risk Gestational Trophoblastic Neoplasia.
Kang HL; Zhao Q; Yang SL; Duan W
Chemotherapy; 2019; 64(1):42-47. PubMed ID: 31163446
[TBL] [Abstract][Full Text] [Related]
3. Factors related to treatment outcomes in low-risk gestational neoplasia.
Turkmen O; Basaran D; Karalok A; Kimyon GC; Tasci T; Ureyen I; Tulunay G; Turan T
Tumori; 2017 Mar; 103(2):177-181. PubMed ID: 27514315
[TBL] [Abstract][Full Text] [Related]
4. Human Chorionic Gonadotropin (hCG) Regression Curve for Predicting Response to EMA/CO (Etoposide, Methotrexate, Actinomycin D, Cyclophosphamide and Vincristine) Regimen in Gestational Trophoblastic Neoplasia.
Rattanaburi A; Boonyapipat S; Supasinth Y
Asian Pac J Cancer Prev; 2015; 16(12):5037-41. PubMed ID: 26163637
[TBL] [Abstract][Full Text] [Related]
5. The value of an initial drop in human Chorionic gonadotropin levels in predicting a response to methotrexate in women with low-risk gestational trophoblastic neoplasia.
Banach P; Zaborowski MP; Izycka N; Romala A; Nowak-Markwitz E
Ginekol Pol; 2019; 90(3):141-147. PubMed ID: 30950003
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for second-line dactinomycin failure after methotrexate treatment for low-risk gestational trophoblastic neoplasia: a retrospective study.
Hoeijmakers YM; Sweep F; Lok C; Ottevanger PB
BJOG; 2020 Aug; 127(9):1139-1145. PubMed ID: 32141676
[TBL] [Abstract][Full Text] [Related]
7. Evaluating methotrexate treatment in patients with low-risk postmolar gestational trophoblastic neoplasia.
Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
Gynecol Oncol; 2009 Feb; 112(2):353-7. PubMed ID: 19059633
[TBL] [Abstract][Full Text] [Related]
8. [Clinical analysis of patients with relapsed and chemo-resistant gestational trophoblastic neoplasia].
Zhou Y; Feng FZ; Xiang Y; Wan XR
Zhonghua Fu Chan Ke Za Zhi; 2010 Nov; 45(11):804-7. PubMed ID: 21211275
[TBL] [Abstract][Full Text] [Related]
9. Low-risk gestational trophoblastic neoplasia and methotrexate resistance: predictors of response to treatment with actinomycin D and need for combination chemotherapy.
Growdon WB; Wolfberg AJ; Goldstein DP; Feltmate CM; Chinchilla ME; Lieberman ES; Berkowitz RS
J Reprod Med; 2010; 55(7-8):279-84. PubMed ID: 20795339
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of weekly intramuscular methotrexate in the treatment of low risk gestational trophoblastic neoplasia.
Hasanzadeh M; Tabari A; Homae F; Shakeri M; Bakhshandeh T; MadaniSani F
J Cancer Res Ther; 2014; 10(3):646-50. PubMed ID: 25313754
[TBL] [Abstract][Full Text] [Related]
11. A 30-year experience in using oral methotrexate as initial treatment for gestational trophoblastic neoplasia regardless of risk group.
Faaborg L; Niemann I; Ostenfeld EB; Hansen ES; Sunde L; Lindegaard JC
Acta Oncol; 2016; 55(2):234-9. PubMed ID: 26106854
[TBL] [Abstract][Full Text] [Related]
12. Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia.
Lybol C; Sweep FC; Harvey R; Mitchell H; Short D; Thomas CM; Ottevanger PB; Savage PM; Massuger LF; Seckl MJ
Gynecol Oncol; 2012 Jun; 125(3):576-9. PubMed ID: 22410329
[TBL] [Abstract][Full Text] [Related]
13. Early prediction of post-molar gestational trophoblastic neoplasia and resistance to methotrexate, based on a single serum human chorionic gonadotropin measurement.
Hoeijmakers YM; Eysbouts YK; Massuger LFAG; Dandis R; Inthout J; van Trommel NE; Ottevanger PB; Thomas CMG; Sweep FCGJ
Gynecol Oncol; 2021 Dec; 163(3):531-537. PubMed ID: 34602288
[TBL] [Abstract][Full Text] [Related]
14. Early prediction of treatment resistance in low-risk gestational trophoblastic neoplasia using population kinetic modelling of hCG measurements.
You B; Harvey R; Henin E; Mitchell H; Golfier F; Savage PM; Tod M; Wilbaux M; Freyer G; Seckl MJ
Br J Cancer; 2013 May; 108(9):1810-6. PubMed ID: 23591194
[TBL] [Abstract][Full Text] [Related]
15. Predictive values of hCG clearance for risk of methotrexate resistance in low-risk gestational trophoblastic neoplasias.
You B; Pollet-Villard M; Fronton L; Labrousse C; Schott AM; Hajri T; Girard P; Freyer G; Tod M; Tranchand B; Colomban O; Ribba B; Raudrant D; Massardier J; Chabaud S; Golfier F
Ann Oncol; 2010 Aug; 21(8):1643-1650. PubMed ID: 20154304
[TBL] [Abstract][Full Text] [Related]
16. Increasing the human chorionic gonadotrophin cut-off to ≤1000 IU/l for starting actinomycin D in post-molar gestational trophoblastic neoplasia developing resistance to methotrexate spares more women multi-agent chemotherapy.
Cortés-Charry R; Hennah L; Froeling FEM; Short D; Aguiar X; Tin T; Harvey R; Unsworth N; Kaur B; Savage P; Sarwar N; Seckl MJ
ESMO Open; 2021 Jun; 6(3):100110. PubMed ID: 33845362
[TBL] [Abstract][Full Text] [Related]
17. Outcome of gestational trophoblastic neoplasia: experience from a tertiary cancer centre in India.
Gulia S; Bajpai J; Gupta S; Maheshwari A; Deodhar K; Kerkar RA; Seth V; Rekhi B; Menon S
Clin Oncol (R Coll Radiol); 2014 Jan; 26(1):39-44. PubMed ID: 24051171
[TBL] [Abstract][Full Text] [Related]
18. [Effects of primary chemotherapy with single methotrexate on low-risk gestational trophoblastic neoplasia and influencing factors thereof].
Chen YX; Shen YM; Qian JH; Xie X
Zhonghua Yi Xue Za Zhi; 2005 Aug; 85(30):2109-12. PubMed ID: 16313819
[TBL] [Abstract][Full Text] [Related]
19. Efficacy analysis of single-agent carboplatin AUC4 2-weekly as second-line therapy for methotrexate-resistant (MTX-R) low risk gestational trophoblastic neoplasia (GTN).
Winter MC; Tidy JA; Singh K; Sarwar N; Aguiar X; Seckl MJ
Gynecol Oncol; 2023 Aug; 175():66-71. PubMed ID: 37327541
[TBL] [Abstract][Full Text] [Related]
20. Transvaginal ultrasound predicts delayed response to chemotherapy and drug resistance in stage I low-risk trophoblastic neoplasia.
Cavoretto P; Gentile C; Mangili G; Garavaglia E; Valsecchi L; Spagnolo D; Montoli S; Candiani M
Ultrasound Obstet Gynecol; 2012 Jul; 40(1):99-105. PubMed ID: 22262502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
